hotspot -WSS

hotspot

author：comprehensive 2025-10-01 12:35:58 - browse：8673

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The Food and Drug Administration on Thursday approved an Eli Lilly drug that takes a new approach to treating ulcerative colitis, a chronic inflammatory disease that can cause intense gastrointestinal pain and distress.

The therapy, dubbed Omvoh, is an antibody that blocks IL-23p19, an immune signaling molecule that plays a key role in sustaining the disease. It’s the first treatment to target this particular pathway in ulcerative colitis. The drug’s approval comes after two late-stage trials found that patients taking Omvoh showed a significant improvement in symptoms after both three months and a year compared with those given a placebo, and that the therapy had minimal side effects.

Omvoh’s list price will be $9,593 per month for intravenous delivery and $10,360 per dose injected beneath the skin. A company spokesperson told STAT that patients who have the drug covered by commercial insurance may pay as little as $5 per month for up to 30 months.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： GSK’s asthma push continues as drug succeeds in Phase 3 trials

knowledge

hotspot

WSS

Brain technologies pose threats that are all too real, experts warn

Elevance PBM president out as customers face prescription chaos

AltruBio raises $225 million to develop ulcerative colitis drug

The effects of a landmark ruling on DNA ownership are becoming clearer

UnitedHealth CEO's Medicaid comments send insurer stocks diving

The effects of a landmark ruling on DNA ownership are becoming clearer

focus

hotspot

explore

Heart attack and stroke risk calculators need revising

Finland to offer bird flu vaccine to select groups of people, a possible global first

Medical leaders decry Supreme Court decision on affirmative action

HHS's proposed rule does nothing to address the climate crisis

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

CMS got Medicare Advantage quality rating wrong, judge rules

How one medical school became remarkably diverse

Anthony Fauci pushes back on GOP claims during Covid hearing

Wildfire smoke exposes gaps in outdoor worker protections

FTC loses bid to block Novant's North Carolina hospital merger

entertainment

The most pressing bird flu mysteries scientists want answered

ASCO Daily Recap: CAR

Class action alleges UnitedHealth concealed DOJ probe

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

Medicare Advantage's lean provider networks lead CMS complaints

How CO2 helps viruses stay alive longer in the air

knowledge

hotspot

hotspot

hotspot